TABLE 1.
Baseline characteristics of the study population
| Patients with adrenal insufficiency | Patients without adrenal insufficiency | p value | |
|---|---|---|---|
| n = 10 | n = 176 | ||
| Sex (M/F), n (%) | 6 (60)/4 (40) | 126 (71.6)/50 (28.4) | 0.48 |
| Age (range) | 67.5 (52–80) | 68.0 (40–78) | 0.61 |
| Smoking history (yes/no), n (%) | 9 (90)/1 (10) | 155 (88.1)/21 (11.9) | 1.00 |
| PD‐L1 expression (≥50%/<50% or unknown), n (%) | 3 (30)/7 (70) | 101 (57.4)/75 (42.6) | 0.11 |
| Driver mutation, n (%) | 4 (40) | 16 (9.1) | 0.01 |
| Performance status (0–1/≥2), n (%) | 9 (90)/1 (10) | 154 (87.5)/22 (12.5) | 1.00 |
| Histology (SQ/non‐SQ), n (%) | 1 (10)/9 (90) | 32 (18.2)/144 (81.8) | 0.51 |
| Stage (I or II/III or IV), n (%) | 1 (10)/9 (90) | 26 (14.8)/150 (85.2) | 1.00 |
| Monotherapy/combination therapy, n (%) | 4 (40)/6 (60) | 109 (62.0)/67 (38.0) | 0.19 |
| Treatment of line (first or second/≥third), n (%) | 8 (80)/2 (20) | 158 (89.8)/18 (10.2) | 0.29 |
| Steroid use before incidence of AI, n (%) | 0 (0) | – |
Note: Comparisons performed by Fisher's exact test and the Mann–Whitney U test as appropriate.
Abbreviations: SQ, squamous cell carcinoma; non‐SQ, non‐squamous cell carcinoma; AI, adrenal insufficiency.